Overview

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the activity and effects of BGJ398 on bladder cancer tumors that are confined to the lining of the bladder.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Infigratinib